x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Few & Far Between: How Biotech Gets Built

Welcome to Few & Far Between! Chris O"Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.

science life sciences

All Episodes

00:38:55

Episode 27, Part 2: Jamie Heywood, Biotech Engineer...

Few & Far Between: How Biotech Gets Built ·

2023/01/31

"Humans have the right to study themselves." -Jamie Heywood, CEO at Alden Scientific Welcome back to Part 2 of our special Few & Far Between podcast episode with guest, Jamie Heywood. Continuing our discussion on the role of engineering in clinical research - and making the world a better place for people - we'll explore the path to innovation, including data tracking strategies and securing project funding.

en

00:38:55

Episode 27, Part 2: Jamie Heywood, Biotech Engineer...

Few & Far Between: How Biotech Gets Built ·

2023/01/31

"Humans have the right to study themselves." - Jamie Heywood, CEO at Alden Scientific Welcome back to Part 2 of our special Few & Far Between podcast episode with guest, Jamie Heywood. Continuing our discussion on the role of engineering in clinical research - and making the world a better place for people - we'll explore the path to innovation, including data tracking strategies and securing project funding.

en

00:33:36

Episode 27, Part 1: Jamie Heywood, Biotech Engineer...

Few & Far Between: How Biotech Gets Built ·

2023/01/12

"I think all disciplines go through a process, a journey of being imagined and then becoming a science and then becoming a discipline of engineering." - Jamie Heywood, CEO at Alden Scientific Biorasi welcomes Jamie Heywood to the Few & Far Between podcast to discuss the critical role engineering plays in clinical research.

en

00:33:36

Episode 27, Part 1: Jamie Heywood, Biotech Engineer...

Few & Far Between: How Biotech Gets Built ·

2023/01/12

"I think all disciplines go through a process, a journey of being imagined and then becoming a science and then becoming a discipline of engineering." - Jamie Heywood, CEO at Alden Scientific Biorasi welcomes Jamie Heywood to the Few & Far Between podcast to discuss the critical role engineering plays in clinical research.

en

00:39:02

Episode 26: Chris Min, CMO and Interim CEO at...

Few & Far Between: How Biotech Gets Built ·

2022/12/07

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials.

en

00:39:02

Episode 26: Chris Min, CMO and Interim CEO at...

Few & Far Between: How Biotech Gets Built ·

2022/12/07

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials.

en

00:39:44

Episode 25: Jim Geraghty, Author and Biotech Industry...

Few & Far Between: How Biotech Gets Built ·

2022/11/17

“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.

en

00:39:44

Episode 25: Jim Geraghty, Author and Biotech Industry...

Few & Far Between: How Biotech Gets Built ·

2022/11/17

“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.

en

00:39:58

Episode 24: Gadi Lachman, President and CEO, TriNetX

Few & Far Between: How Biotech Gets Built ·

2022/10/06

Can data sharing make the world a better place? Listen in to the latest episode of Few & Far Between. Biorasi CEO, Chris O'Brien, welcomes Gadi Lachman, President and CEO of TriNetX, to discuss real-world solutions foraccessing and refining patient data in the clinical trials industry.

en

00:39:58

Episode 24: Gadi Lachman, President and CEO, TriNetX

Few & Far Between: How Biotech Gets Built ·

2022/10/06

Can data sharing make the world a better place? Listen in to the latest episode of Few & Far Between. Biorasi CEO, Chris O'Brien, welcomes Gadi Lachman, President and CEO of TriNetX, to discuss real-world solutions for accessing and refining patient data in the clinical trials industry.

en

00:37:26

Episode 23: Dr. Arun Bhatt, Consultant for Clinical...

Few & Far Between: How Biotech Gets Built ·

2022/09/14

What makes India a smart and viable setting for today’s clinical trials?Join us for the latest episode of Few & Far Between. Biorasi'sown Dr. Sagar Patil welcomes one of his early mentors, Dr. Arun Bhatt, for an in-depth discussion into the history and future of clinical research in India.

en

00:37:26

Episode 23: Dr. Arun Bhatt, Consultant for Clinical...

Few & Far Between: How Biotech Gets Built ·

2022/09/14

What makes India a smart and viable setting for today’s clinical trials? Join us for the latest episode of Few & Far Between. Biorasi's own Dr. Sagar Patil welcomes one of his early mentors, Dr. Arun Bhatt, for an in-depth discussion into the history and future of clinical research in India.

en

00:23:58

Episode 22: Dr. Jocelynn Pearl, Senior Scientist at...

Few & Far Between: How Biotech Gets Built ·

2022/07/26

How can DAOs - Decentralized Autonomous Organizations - improve rare disease research? Biorasi's Few & Far Between Podcast welcomes Dr. Jocelynn Pearl, Senior Scientist at Tune Therapeutics and host of the Lady Scientist podcast, to discuss this new connection between clinical trials and cryptocurrency.

en

00:23:58

Episode 22: Dr. Jocelynn Pearl, Senior Scientist at...

Few & Far Between: How Biotech Gets Built ·

2022/07/26

How can DAOs - Decentralized Autonomous Organizations - improve rare disease research? Biorasi's Few & Far Between Podcast welcomes Dr. Jocelynn Pearl, Senior Scientist at Tune Therapeutics and host of the Lady Scientist podcast, to discuss this new connection between clinical trials and cryptocurrency.

en

00:36:29

Episode 21: Jill Hawkins, Founder and President of...

Few & Far Between: How Biotech Gets Built ·

2022/06/23

How do you start in building a rare disease foundation? Biorasi's Few & Far Between Podcast Welcomes Jill Hawkins, Founder and President of the FAM177A1 Research Fund, to discuss the impact of an ultrarare disease on her family and the importance of moving forward towards awareness, support, and treatment.

en

00:36:29

Episode 21: Jill Hawkins, Founder and President of...

Few & Far Between: How Biotech Gets Built ·

2022/06/23

How do you start in building a rare disease foundation? Biorasi's Few & Far Between Podcast Welcomes Jill Hawkins, Founder and President of the FAM177A1 Research Fund, to discuss the impact of an ultrarare disease on her family and the importance of moving forward towards awareness, support, and treatment.

en

00:30:43

Episode 20: Professor Bertil E. Lindmark MD, PhD,...

Few & Far Between: How Biotech Gets Built ·

2022/05/18

What do the next 100 years have in store for healthcare and clinical research? Biorasi's Few & Far Between podcast welcomes Professor Bertil E. Lindmark MD, PhD, author and CMO at Galecto, Inc., for an in-depth discussion on the biological revolution and trends in the life sciences.

en

00:30:43

Episode 20: Professor Bertil E. Lindmark MD, PhD,...

Few & Far Between: How Biotech Gets Built ·

2022/05/18

What do the next 100 years have in store for healthcare and clinical research? Biorasi's Few & Far Between podcast welcomesProfessor Bertil E. Lindmark MD, PhD, author and CMO at Galecto, Inc., for an in-depth discussion on the biological revolution and trends in the life sciences.

en

00:36:19

Episode 19: Leslie Michelson, Founder and CEO,...

Few & Far Between: How Biotech Gets Built ·

2022/04/20

How do you obtain the best possible patient care available? On this week's Few & Far Between podcast, host Chris O'Brien welcomes patient advocacy innovator Leslie Michelson for a conversation on the importance of patient support, guidance, and healthcare accessibility.

en

00:36:19

Episode 19: Leslie Michelson, Founder and CEO,...

Few & Far Between: How Biotech Gets Built ·

2022/04/20

How do you obtain the best possible patient care available? On this week's Few & Far Between podcast, host Chris O'Brien welcomes patient advocacy innovator Leslie Michelson for a conversation on the importance of patient support, guidance, and healthcare accessibility.

en

121 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter